Alivus Life Sciences Ltd Q1 FY27 Earnings Analysis

- Non-GPL business is already growing at double-digit; expected to continue outpacing GPL business. - Overall sales volume growth across segments is significant and expected to persist. - New product launches contribute to growth, though not yet a major revenue driver. - Capacity expansions (Solapur greenfield, brownfield expansions at Ankleshwar and Dahej) will enable volume and revenue growth post ramp-up. - Solapur Phase 1 expected to start with 40-50% utilization, scaling to 60-70% gradually. - New launches and pipeline buildup (especially complex molecules and high-potent APIs) underpin medium- to long-term growth. - CDMO business ramping up with new projects commencing, supporting future revenue momentum. - Balanced geographic diversification (India, Europe, Latin America, US, Japan) aids steady growth. - Focus remains on profitable, high-quality growth rather than volume at cost of margins.

- The company aims for sustained profitable growth by focusing on unique, high-entry-barrier products, fostering differentiation and sustainable margins. - Non-GPL business is growing at double-digit rates, expected to continue, reducing dependency on GPL business. - Gross margins improved to 58.2% in FY26 with a target to maintain EBITDA margins between 30%-32%. - New capacity additions, especially from Solapur and brownfield expansions, will enable revenue growth from FY28 onwards. - CDMO segment is gaining momentum, with new projects and contract deals expected in H2 FY27, contributing to future growth. - R&D spend is set to stabilize around 4% of sales, driving innovation in flow chemistry, high-potent APIs, pellets, and granules. - Price erosion in base non-GPL, non-CDMO business is approximately 5.5% but offset by volume growth. - Overall revenue CAGR was 5.7% (FY24-FY26) with EBITDA CAGR at 15.8%; double-digit top-line growth targeted in non-GPL segments. - Capex of INR540 crores planned for FY27, funded via internal accruals, supporting capacity and product pipeline expansion.

- FY27 capex planned at about INR 540 crores, including carryover from FY26 and fresh investments. - Entire capex funded through internal accruals. - Investments focus on building new capabilities at Solapur (greenfield project) and strengthening the R&D platform. - Capacity expansion to increase from 1,198 KL in FY24 to a planned 2,690 KL by FY28. - Solapur facility: Phase 1 includes 370 KL for BI block and 120 KL for API block, with 40-50% initial utilization. - Brownfield expansions at Ankleshwar and Dahej, with rapid ramp-up expected within 2-3 quarters. - Solapur has land bank for additional 700-800 KL capacity, offering runway for 3-4 years. - R&D spend expected to rise to about 4% of sales over the next 1-2 years and then stabilize. - Focus areas: flow chemistry, high potent APIs, pellets and granules, and lateral expansion of the API portfolio.

- There is no mention of any current or planned fundraising through debt or equity in the provided document. - The company plans a capex of about INR540 crores for FY27. - This entire capex will be funded through internal accruals, indicating no need for external financing. - The cash position is strong, with cash and cash equivalents at INR782 crores as of March 31, 2026. - There is confidence expressed in maintaining investment and growth without the need for external fundraising.

- Alivus Life Sciences operates primarily on long-term contracts in its CDMO business. - In the generic API segment, contracts are fewer and typically short-term, lasting about 1-2 years. - The company prefers short to medium-term contracts to maintain flexibility due to a dynamic environment. - This flexibility helps them respond to market changes, such as price increases related to external factors (e.g., war situations). - Orders are generally placed by customers as needed, without getting locked into cumbersome clauses. - No specific figures on current or expected orderbook/pending orders were disclosed in the transcript.